Review Article

Antitumor pharmacological research in the era of personalized medicine

Min Huang1,2, Mei-yu Geng1,2, Jian Ding1,2
1 State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
2 University of Chinese Academy of Sciences, Beijing 100049, China
Correspondence to: Jian Ding:,
DOI: 10.1038/s41401-022-01023-0
Received: 27 September 2022
Accepted: 2 November 2022
Advance online: 24 November 2022


Anticancer drug discovery has yielded unprecedented progress in recent decades, resulting in the approval of innovative treatment options for patients and the successful implementation of personalized medicine in clinical practice. This remarkable progress has also reshaped the research scope of pharmacological research. This article, as a tribute to cancer research at Shanghai Institute of Materia Medica in celebration of the institute’s 90th birthday, provides an overview of the conceptual revolution occurring in anticancer therapy, and summarizes our recent progress in the development of molecularly targeted therapeutics and exploration of new strategies in personalized medicine. With this review, we hope to provide a glimpse into how antitumor pharmacological researchers have embraced the new era of personalized medicine research and to propose a future path for anticancer drug discovery and pharmacological research.
Keywords: personalized medicine; anticancer drug discovery; oncogene addiction; non-oncogene addiction; combination therapy

Article Options

Download Citation

Cited times in Scopus